News
Public · Published
VIJAYA: Revenue grew 26.7% as volume gains and operating leverage lifted Q2 margins to 44.1%
Vijaya Diagnostic Centre reported Q2 revenue growth of 26.7% year over year. Its EBITDA margin, meaning the share of revenue remaining after operating costs before interest, taxes and certain other expenses, rose 350 basis points to 44.1%, supported by higher volume, test mix and operating leverage. The company guided to at least 20% growth in FY27 and continued hub-and-spoke expansion.
Published:
Updated:
What happened
Vijaya Diagnostic Centre reported Q2 revenue growth of 26.7% year over year. Its EBITDA margin, meaning the share of revenue remaining after operating costs before interest, taxes and certain other expenses, rose 350 basis points to 44.1%, supported by higher volume, test mix and operating leverage. The company guided to at least 20% growth in FY27 and continued hub-and-spoke expansion.
Confirmed
Global impact / market context
Higher test volumes and a more favorable mix of tests can increase revenue, while operating leverage means costs grow more slowly than sales. If these drivers continue, the company could sustain stronger profit per sale as it expands its hub-and-spoke network, though expansion costs could temper gains.
Analyst inference
The update combines reported Q2 growth and margin expansion with a forward growth goal and continued network expansion. For investors, the key link is whether new hubs and spokes add enough testing volume and revenue to cover their operating and setup costs without weakening margins.
Analyst inference
What to watch
- Check future results for revenue growth against the at-least-20% FY27 guidance, since slower growth could indicate that recent volume gains are not continuing. Analyst inference
- Watch whether the company continues hub-and-spoke expansion and whether its updates describe the pace or costs of adding locations. Confirmed
- Track EBITDA margin, the share of revenue left after operating costs before interest and taxes, to see whether volume and test mix offset expansion costs. Analyst inference
Evidence
- Original source link unavailable